Molecular Formula	C14H15N3O5
Molecular Weight	305.29
Structure
State	solid
Clearance	* 850 mL/min
Volume of distribution	* 20 L
Route of elimination	Entacapone is almost completely metabolized prior to excretion, with only a very small amount (0.2% of dose) found unchanged in urine. As only about 10% of the entacapone dose is excreted in urine as parent compound and conjugated glucuronide, biliary excretion appears to be the major route of excretion of this drug.
Protein binding	98% (bind to serum albumin)
Half life	0.4-0.7 hour
Absorption	Entacapone is rapidly absorbed (approximately 1 hour). The absolute bioavailability following oral administration is 35%.
Trade names	Comtan
Description	selective, reversible catechol-O-methyl transferase (COMT) inhibitor; a member of the class of nitrocatechols; methyl-transferase inhibitor; contain the nitrophenol protonophore

Toxicity	Dose	Time	Species	Model	Method	Action	Positive criterion	Reference
UNCOUPLING						increase		35
ASSOCIATE WITH UNCOUPLING			rat	liver mitochondria	RST assay( Respiratory Screening Technology)-measurement of oxygen consumption in isolated mitochondria using a phosphorescent oxygen-sensitive probe A65N-1	affect		204
OXYGEN CONSUMPTION RATE (OCR)	33 μM	2 minutes	human	HepG2	Measurement of OCR	increase	EC50	7
ECAR	100 μM	2 minutes	human	HepG2	Measurement of ECAR	increase	EC50	7

Pictogram	Signal	Statements	Precautionary Statement Codes
	Warning	Aggregated GHS information provided by 4 companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. Reported as not meeting GHS hazard criteria by 1 of 4 companies. For more detailed information, please visit ECHA C&L website Of the 3 notification(s) provided by 3 of 4 companies with hazard statement code(s): H302 (33.33%): Harmful if swallowed [Warning Acute toxicity, oral] H315 (66.67%): Causes skin irritation [Warning Skin corrosion/irritation] H319 (66.67%): Causes serious eye irritation [Warning Serious eye damage/eye irritation] H332 (33.33%): Harmful if inhaled [Warning Acute toxicity, inhalation] H335 (33.33%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposure Respiratory tract irritation] H413 (33.33%): May cause long lasting harmful effects to aquatic life [Hazardous to the aquatic environment, long-term hazard] Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.	P261, P264, P270, P271, P273, P280, P301+P312, P302+P352, P304+P312, P304+P340, P305+P351+P338, P312, P321, P330, P332+P313, P337+P313, P362, P403+P233, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.)

Parkinson's disease

Parkinsonism

Abdominal pain

Agitation

Anxiety

Asthenia

Back pain

Bacterial infection

Chromaturia

Constipation

Depression

Diarrhoea

Dizziness

Dry mouth

Dysgeusia

Dyskinesia

Dyspepsia

Dyspnoea

Fatigue

Flatulence

Gastritis

Gastrointestinal disorder

Gastrointestinal pain

Hallucination

Headache

Hyperhidrosis

Hyperkinesia

Hypokinesia

Insomnia

Muscle spasms

Nausea

Orthostatic hypotension

Pain

Parkinsonism

Purpura

Somnolence

Tremor

Vascular purpura

Vertigo

Vomiting

(2E)-2-Cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-2-propenamide	(2E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide	(E)-2-CYANO-3-(5-(DIHYDROXYAMINO)-3,4-DIOXOCYCLOHEXA-1,5-DIENYL)-N,N-DIETHYLACRYLAMIDE
(E)-2-Cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-2-propenamide	(E)-2-cyano-3-(3,4-dihydroxy-5-nitro-phenyl)-N,N-diethyl-prop-2-enamide	(E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylacrylamide
(E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide	(E)-2-cyano-N,N-diethyl-3-[3-nitro-4,5-bis(oxidanyl)phenyl]prop-2-enamide	(E)-Entacapone
(E)-N, N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide	(E)-N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide	(E)-alpha-Cyano-N,N-diethyl-3,4-dihydroxy-5-nitrocinnamamide
(~{E})-2-cyano-~{N},~{N}-diethyl-3-[3-nitro-4,5-bis(oxidanyl)phenyl]prop-2-enamide	116314-67-1	130929-57-6
2-Cyano-N,N-diethyl-3-(3,4-dihydroxy-5-nitrophenyl)propenamide	2-Propenamide, 2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-	2-Propenamide, 2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-, (2E)-
2-Propenamide,2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-,(2E)-	2-cyano-3-(5-dihydroxyamino-3,4-dioxo-1-cyclohexa-1,5-dienyl)-N,N-diethyl-prop-2-enamide	4975G9NM6T
929E576	A806167	AB0105766
AB01275450-01	AB01275450_02	AB01275450_03
AC-393	AKOS015907685	AKOS015965009
BCP9000645	BDBM50108879	BG0523
BIDD:GT0026	BRD-K83636919-001-01-4	C07943
C14H15N3O5	CAS-130929-57-6	CCG-213064
CHEBI:4798	CHEMBL953	COM-998
CS-1266	Comtan	Comtan (TN)
Comtess	D00781	DB00494
DSSTox_CID_26439	DSSTox_GSID_46439	DSSTox_RID_81615
DTXSID5046439	ENTACAPONE	EX-A1130
Entacapona	Entacapona [INN-Spanish]	Entacapone (JP17/USAN/INN)
Entacapone [USAN:INN]	Entacapone [USAN:USP:INN:BAN]	Entacaponum
Entacaponum [INN-Latin]	Entacom	GP9755
GTPL6647	HMS2089O16	HMS3713B20
HSDB 8251	HY-14280	J-005902
J-008069	J90011	JRURYQJSLYLRLN-BJMVGYQFSA-N
K-4072	LS-123327	LS-172316
N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl) acrylamide	NCGC00164555-01	NCGC00164555-02
NCGC00164555-03	OR 611	OR-611
PD9	Q416444	RT-012475
SCHEMBL13596593	SCHEMBL34504	SCHEMBL34505
SR-05000001452	SR-05000001452-1	SR-05000001452-2
SR-05000001452-3	SW199035-2	Tox21_112184
Tox21_112184_1	UNII-4975G9NM6T	ZINC35342787
cis-Entacapone	s3147

DrugBank Name	Entacapone
DrugBank	DB00494
CAS Number	1047659-02-8, 116314-67-1, 130929-57-6
PubChem Compound	5281081
KEGG Compound ID	C07943
KEGG Drug	D00781
PubChem.Substance	46508734
ChEBI	4798
PharmGKB	PA164748726
ChemSpider	4444537
BindingDB	50108879.0
TTD	DAP000608
Wikipedia	Entacapone
DPD	12126